About us

We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high medical need. Using blood as a liquid biopsy can improve patient access to cancer screening and thereby contribute to eradicate today’s deadliest cancer types such as lung and colorectal cancer. By leveraging our product pipeline and strong intellectual property, we aim to become a global leader in blood-based cancer detection.